|1.||Villalpando-Vargas, Fridha: 1 article (10/2015)|
|2.||Medina-Ceja, Laura: 1 article (10/2015)|
|3.||Grotthus, Bartosz: 1 article (03/2007)|
|4.||Czarnik-Matusewicz, Henryk: 1 article (03/2007)|
|5.||Hurkacz, Magdalena: 1 article (03/2007)|
|6.||Rudzik, Jacek: 1 article (03/2007)|
|7.||Orzechowska-Juzwenko, Krystyna: 1 article (03/2007)|
|8.||Milejski, Piotr: 1 article (03/2007)|
|9.||Leszek, Jerzy: 1 article (03/2007)|
|10.||Niewiński, Przemysław: 1 article (03/2007)|
06/01/1993 - "We have determined sensitivity to painful stimuli in 94 extensive metabolisers and 82 poor metabolisers of sparteine in 2 phasic (pain thresholds to heat and pressure) and 1 tonic (cold pressor test) experimental pain model. "
01/01/1996 - "The objective of the present study was to assess the analgesic effect of codeine on different types of experimental pain in relation to sparteine phenotype. "
12/01/1996 - "The analgesic effect of 2 mg/kg tramadol was evaluated in 15 extensive and 12 poor metabolizers of sparteine in two parallel, randomized, double-blind, placebo-controlled crossover studies that used experimental pain models. "
06/01/1993 - "Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?"
08/01/1998 - "This study aimed at evaluating the impact of sparteine phenotype and serum concentrations of morphine on the efficacy of codeine in post-operative pain. "
10/22/2015 - "These results support the anticonvulsant effect of low doses of sparteine and allow us to direct our efforts to other new anticonvulsant strategies for seizure treatment. "
10/22/2015 - "After sparteine pretreatment (13mg/kg, administered 30min before the convulsive drug), the animals administered pentylenetetrazole and pilocarpine exhibited reduced mortality rates compared with the corresponding control groups, while the animals administered kainic acid exhibited a delayed onset of convulsive behavior and decreased seizure duration compared with the corresponding control group. "
01/01/1982 - "[Experimental studies on therapeutic modification of sparteine poisoning]."
04/01/1973 - "[EKG changes in acute pachycarpine poisoning]."
03/01/1971 - "[Acute pachycarpine poisoning in obstetrical practice]."
09/01/1969 - "[A case of successful reanimation after pachycarpine poisoning]."
09/01/1968 - "[A case of recovery from clinical death due to pachycarpine poisoning under home conditons]."
|4.||Parkinson Disease (Parkinson's Disease)
09/01/1999 - "The phenotyping of oxidation revealed two distinct populations among 50 patients with Parkinson's disease: 47 persons (94%) were extensive metabolizers of sparteine and 3 persons (6%) were poor metabolizers. "
09/01/1999 - "The aim of our study was to evaluate whether patients with Parkinson's disease differ from healthy persons in their ability to oxidize sparteine and acetylate sulfadimidine as model drugs. "
12/01/1998 - "We conclude that there is no convincing evidence of an association between the debrisoquine/sparteine polymorphism and Parkinson's disease. "
03/01/1993 - "[Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson's disease]."
12/01/1998 - "The association between the sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease was examined in a meta-analysis of case-control studies. "
|5.||Atrial Flutter (Flutter, Atrial)
|1.||Codeine (Codeine Phosphate)
|2.||Morphine (MS Contin)
|5.||Kainic Acid (Kainate)
|9.||Cytochrome P-450 CYP2D6 (CYP2D6)